

JUL 20 2007

Appl. No. 10/733,042  
Reply to Office action of April 20, 2007

This listing of claims will replace all prior versions and listings of claims in the application:

**Listing of Claims:**

1. (amended) ~~An isolated nucleic acid molecule~~ The nucleic acid molecule of claim 6 comprising an avian matrix attachment region and an avian ovalbumin transcriptional regulatory region.
2. (amended) The nucleic acid molecule ~~according to of Claim 6 1, further comprising a second~~ matrix attachment region.
3. (amended) The nucleic acid molecule ~~according to of Claim 6 1, comprising an avian 5'~~ matrix attachment region and an avian 3' matrix attachment region.
4. (amended) The nucleic acid molecule ~~according to of Claim 6 1, wherein the nucleic acid~~ molecule is isolated from a chicken cell.
5. (canceled)
6. (amended) ~~The nucleic acid molecule according to Claim 1, A nucleic acid molecule~~ comprising a nucleotide sequence having at least about 95% identity to the nucleotide sequence ~~according to of~~ SEQ ID NO: 1, or the complement thereof.
7. (amended) The nucleic acid molecule ~~according to of Claim 6 1, comprising a nucleotide~~ sequence having at least about 99% identity to the nucleotide sequence ~~according to of~~ SEQ ID NO: 1, or the complement thereof. -
8. (amended) The nucleic acid molecule ~~according to of Claim 6 1, comprising the nucleotide~~ sequence ~~according to of~~ SEQ ID NO: 1, or the complement thereof.

Appl. No. 10/733,042

Reply to Office action of April 20, 2007

9. (amended) The nucleic acid molecule ~~according to~~ of Claim 6 ~~1~~, wherein the nucleic acid molecule consists of the nucleotide sequence ~~according to~~ of SEQ ID NO: 1, or the complement thereof.
10. (canceled)
11. (canceled)
12. (canceled)
13. (canceled)
14. (canceled)
15. (canceled)
16. (canceled)
17. (canceled)
18. (canceled)
19. (canceled)
20. (canceled)
21. (canceled)
22. (canceled)

Appl. No. 10/733,042  
Reply to Office action of April 20, 2007

23. (amended) A vector ~~having inserted therein a nucleic acid molecule according to Claim 1~~ comprising a nucleotide sequence having at least about 95% identity to the nucleotide sequence of SEQ ID NO: 1.
24. (amended) The vector ~~according to~~ of Claim 23 selected from the group consisting of an artificial chromosome, a plasmid vector and a viral vector.
25. (amended) A liposome composition comprising a ~~the~~ nucleic acid molecule ~~according to~~ of Claim 1.
26. (amended) ~~The nucleic acid molecule according to Claim 1;~~ A nucleic acid molecule comprising a nucleotide sequence having at least about 95% identity to the nucleotide sequence of SEQ ID NO: 1 wherein the nucleic acid molecule is a recombinant nucleic acid molecule.
27. (canceled)
28. (canceled)
29. (amended) The recombinant nucleic acid molecule ~~according to~~ of Claim 26; further comprising a first polypeptide-encoding region ~~heterologous nucleic acid sequence~~ operably linked to the ovalbumin transcriptional regulatory region.
30. (amended) The recombinant nucleic acid molecule ~~according to~~ of Claim 26; further comprising an endogenous nucleic acid sequence operably linked to the ovalbumin transcriptional regulatory region.
31. (amended) The recombinant nucleic acid molecule ~~according to~~ of Claim 26; wherein the ovalbumin transcriptional regulatory region is capable of tissue-specific transcription by an avian oviduct cell.

Appl. No. 10/733,042  
Reply to Office action of April 20, 2007

32. (amended) The recombinant nucleic acid molecule ~~according to~~ of Claim 26; further comprising an Internal Ribosome Entry Site.
33. (amended) The recombinant nucleic acid molecule ~~according to~~ of Claim ~~29~~ 32; further comprising a ~~second heterologous nucleic acid sequence~~ polypeptide encoding region operably linked to the Internal Ribosome Entry Site.
34. (canceled)
35. (amended) The vector ~~according to~~ of Claim 34 selected from the group consisting of a bacterial artificial chromosome, a yeast artificial chromosome, a plasmid vector and a viral vector.
36. (amended) The recombinant nucleic acid molecule ~~according to~~ of Claim 26; further comprising a polyadenylation signal sequence.
37. (amended) The recombinant nucleic acid molecule ~~according to~~ of Claim 29; wherein the ~~heterologous~~ nucleic acid sequence encoding the ~~encodes a~~ polypeptide has ~~having~~ a codon complement optimized for protein expression in an avian.
38. (amended) The recombinant nucleic acid molecule ~~according to~~ of Claim 26 further comprising an origin of replication selected from the group consisting of a bacterial origin of replication and a viral origin of replication.
39. (amended) The recombinant nucleic acid molecule ~~according to~~ of Claim 26 which A nucleic acid molecule comprising a nucleotide sequence having at least about 95% identity to the nucleotide sequence ~~according to~~ of SEQ ID NO: 1 comprises ~~is~~ a bacterial artificial chromosome.

Appl. No. 10/733,042  
Reply to Office action of April 20, 2007

40. (canceled)

41. (canceled)

42-70 (canceled)

71. (new) The nucleic acid molecule of Claim 6 comprising a heterologous coding sequence encoding a pharmaceutical protein.

72. (new) The vector of Claim 23 comprising a heterologous coding sequence encoding a pharmaceutical protein.

73. (new) The nucleic acid molecule of Claim 26 comprising a heterologous coding sequence encoding a pharmaceutical protein.

74. (new) The vector of Claim 23 comprising a nucleotide sequence having at least about 99% identity to the nucleotide sequence of SEQ ID NO: 1.

75. (new) The vector of Claim 23 comprising the nucleotide sequence of SEQ ID NO: 1.

76. (new) A MAR element between nucleotide 41701 and nucleotide 41900 of SEQ ID NO: 1.

77. (new) A MAR element between nucleotide 96401 and nucleotide 96800 of SEQ ID NO: 1.